Positive News SentimentPositive News Globus Medical Stock Price, News & Analysis (NYSE:GMED) $44.44 -0.90 (-1.99%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$44.40▼$45.7250-Day Range$43.78▼$55.1452-Week Range$43.38▼$80.04Volume1.02 million shsAverage Volume1.43 million shsMarket Capitalization$6.12 billionP/E Ratio28.67Dividend YieldN/APrice Target$65.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Globus Medical MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside46.5% Upside$65.11 Price TargetShort InterestHealthy2.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment1.56Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth15.15%From $2.31 to $2.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.47 out of 5 starsMedical Sector3rd out of 957 stocksSurgical & Medical Instruments Industry2nd out of 78 stocks 4.1 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.11, Globus Medical has a forecasted upside of 46.5% from its current price of $44.44.Amount of Analyst CoverageGlobus Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.67% of the outstanding shares of Globus Medical have been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Globus Medical has recently decreased by 7.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 3.6 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Globus Medical this week, compared to 4 articles on an average week.Search Interest5 people have searched for GMED on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have not sold or bought any company stock.Percentage Held by Insiders24.30% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.54% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 15.15% in the coming year, from $2.31 to $2.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 28.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 28.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.52.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Globus Medical Stock (NYSE:GMED)Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Read More GMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMED Stock News HeadlinesDecember 1, 2023 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?November 27, 2023 | seekingalpha.comGlobus Medical: Merger Overhang LingeringDecember 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 10, 2023 | markets.businessinsider.comGlobus Medical Stock Receives Sell Rating: Weak NUVA Performance and Integration Risks HighlightedNovember 8, 2023 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comGlobus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to SayNovember 7, 2023 | finance.yahoo.comGlobus Medical (GMED) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | finance.yahoo.comWhen Should You Buy Globus Medical, Inc. (NYSE:GMED)?December 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 6, 2023 | finance.yahoo.comWhy Globus Medical (GMED) is Poised to Beat Earnings Estimates AgainOctober 25, 2023 | markets.businessinsider.comHold Rating on Globus Medical Amid Integration Concerns and Q3 Sales ExpectationsOctober 24, 2023 | finance.yahoo.comFive-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual MeetingOctober 21, 2023 | finance.yahoo.com33% earnings growth over 1 year has not materialized into gains for Globus Medical (NYSE:GMED) shareholders over that periodOctober 20, 2023 | msn.comRoth MKM Initiates Coverage of Globus Medical Inc - (GMED) with Buy RecommendationOctober 20, 2023 | msn.comRoth MKM starts Globus Medical at buy, calls it "dominant force in spine"October 10, 2023 | finance.yahoo.comTwenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual ForumOctober 5, 2023 | finance.yahoo.comHere's Why You Should Buy Globus Medical (GMED) Stock NowOctober 3, 2023 | finance.yahoo.comUnveiling Globus Medical's True Worth: Is It Priced Right? A Comprehensive GuideOctober 3, 2023 | finance.yahoo.comUnveiling the Investment Potential of Globus Medical Inc (GMED): A Comprehensive Analysis of ...October 3, 2023 | finance.yahoo.comWith 63% ownership of the shares, Globus Medical, Inc. (NYSE:GMED) is heavily dominated by institutional ownersSeptember 19, 2023 | msn.comStifel Upgrades Globus Medical Inc - (GMED)September 19, 2023 | markets.businessinsider.comGlobus Medical's Untapped Potential Beyond The NUVA Transaction; Analyst Turns BullishSeptember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Align Tech (ALGN) and Globus Medical (GMED)September 13, 2023 | seekingalpha.comGlobus Medical: Almost Having My BackSeptember 8, 2023 | finance.yahoo.comGlobus Medical (GMED) Launches NuVasive's NSO in Global MarketSeptember 7, 2023 | finance.yahoo.comNuVasive Specialized Orthopedics Launches Precice Bone Transport in International MarketsSeptember 6, 2023 | nasdaq.comTruist Securities Reiterates Globus Medical Inc - (GMED) Hold RecommendationSee More Headlines Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees2,600Year FoundedN/APrice Target and Rating Average Stock Price Target$65.11 High Stock Price Target$86.00 Low Stock Price Target$53.00 Potential Upside/Downside+46.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio28.67 Forward P/E Ratio19.24 P/E Growth1.74Net Income$190.17 million Net Margins12.88% Pretax Margin16.51% Return on Equity9.79% Return on Assets8.24% Debt Debt-to-Equity Ratio0.10 Current Ratio4.47 Quick Ratio2.36 Sales & Book Value Annual Sales$759.12 million Price / Sales8.07 Cash Flow$2.75 per share Price / Cash Flow16.16 Book Value$18.43 per share Price / Book2.41Miscellaneous Outstanding Shares137,790,000Free Float104,309,000Market Cap$6.12 billion OptionableOptionable Beta1.06 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. David C. Paul (Age 56)Co-Founder & Executive Chairman Comp: $1.09MMr. Daniel T. Scavilla (Age 58)President, CEO & Director Comp: $1.37MMr. Keith W. Pfeil (Age 44)Senior VP & CFO Comp: $675.89kMs. Kelly G. Huller Esq. (Age 51)Senior VP, General Counsel & Secretary Comp: $543.24kMr. Brian J. Kearns (Age 56)Senior Vice President of Business Development & Investor Relations Key CompetitorsIntegra LifeSciencesNASDAQ:IARTTeleflexNYSE:TFXAlphatecNASDAQ:ATECAtriCureNASDAQ:ATRCInsuletNASDAQ:PODDView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 7,165 shares on 12/6/2023Ownership: 0.022%Wellington Management Group LLPBought 435,132 shares on 12/1/2023Ownership: 1.930%American Century Companies Inc.Bought 11,044 shares on 11/30/2023Ownership: 0.017%Banque Pictet & Cie SABought 81,299 shares on 11/27/2023Ownership: 0.063%Deutsche Bank AGSold 72,809 shares on 11/24/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions GMED Stock Analysis - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price target for 2024? 12 brokers have issued 12 month price objectives for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they predict the company's share price to reach $65.11 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2023? Globus Medical's stock was trading at $74.27 at the beginning of 2023. Since then, GMED stock has decreased by 40.2% and is now trading at $44.44. View the best growth stocks for 2023 here. Are investors shorting Globus Medical? Globus Medical saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 3,680,000 shares, a decrease of 7.8% from the October 31st total of 3,990,000 shares. Based on an average daily volume of 2,000,000 shares, the days-to-cover ratio is currently 1.8 days. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our GMED earnings forecast. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings results on Tuesday, November, 7th. The medical device company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.03. The medical device company had revenue of $383.60 million for the quarter, compared to the consensus estimate of $306.78 million. Globus Medical had a trailing twelve-month return on equity of 9.79% and a net margin of 12.88%. The company's revenue was up 51.0% on a year-over-year basis. During the same period last year, the business posted $0.50 earnings per share. What ETFs hold Globus Medical's stock? ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Health Care Equipment ETF (XHE) and First Trust Health Care AlphaDEX Fund (FXH).iShares U.S. Medical Devices ETF (IHI). What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $2.30 for the period, compared to the consensus EPS estimate of $2.30. The company issued revenue guidance of $1.55 billion, compared to the consensus revenue estimate of $1.13 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). Who are Globus Medical's major shareholders? Globus Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Nuance Investments LLC (3.60%), Wellington Management Group LLP (1.93%), Bank of New York Mellon Corp (2.40%), William Blair Investment Management LLC (2.31%), Hawk Ridge Capital Management LP (2.22%) and JPMorgan Chase & Co. (2.12%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil and Kelly Huller. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:GMED) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.